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Abstract: 
Background and objectives: Lamivudine therapy for chronic hepatitis B (CHB) is associated 
with resistance. This study aimed to analyze the response, the incidence of LAM resistance, 
and different viral mutational patterns of Lamivudine therapy.  
Study design: CHB patients (n=31) who had not previously received interferon or a nucleo-
side analogue, received Lamivudine once daily for a minimum of E12 months and followed. 
All patients were tested for presence of mutation in YMDD motif of viral polymerase gene at 
the end of the first year of treatment, and if indicated in rising alanine aminotransferase 
(ALT) or HBVDNA titer. Polymerase chain reaction along with restriction fragment length 
polymorphism (PCR-RFLP) method was used to detect mutations in YMDD motif.  
Results: The mean age of patients was 45.2 (SD 13.5) years. The mean follow-up period of 
patients was 45.5 (21.9) months. Seventeen patients (54.8%) had mutations, and 45.2% of 
subjects were sensitive to LAM. Mean time of mutation detection after treatment was 45.5 
(SD 25.3) months. The distribution of YMDD status was: 32.3 % YIDD, 3.2% YSDD, 12.9% 
YVDD, and 6.5% YVDD/ YIDD. The mean age, pretreatment HBeAg negativity, and high 
HBVDNA titer at time of mutation had significant statistical association with occurrence of 
YMDD mutants (PV= 0.009, 0.032, 0.049), respectively. 
Conclusions: Lamivudine-resistant mutation is common in CHB patients. Regarding different 
mutant strains as identified in this study, is necessary for develop more useful treatment 
strategies, especially in patients without YMDD mutation and high HBVDNA titer, analysis for 
possible new mutants should be performed.  
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Background: 
Hepatitis B viral (HBV) infection is a ma-
jor health burden in the Asia-Pacific re-
gion.(1) Patients with elevated alanine 
aminotransferase (ALT) and HBV DNA 
levels are candidates for antiviral thera-
py. In patients with HBeAg-positive CHB, 
antiviral treatment is indicated when the 
serum HBV DNA level is 20 000 IU/mL 
and the ALT level is elevated. For HBeAg-
negative patients, the threshold for initia-
tion of therapy is lower, i.e., a serum 
HBV DNA level 2 000 IU/mL in associa-
tion with an elevated ALT level. The 
presence of at least moderate necroin-
flammation and the presence of fibrosis 
on liver biopsy may be useful in support-
ing the decision to initiate therapy, par-
ticularly in patients with normal ALT le-
vels.(2) 
Several studies have shown that increas-
ing HBV viral level, starting at 104 cop-
ies/mL, is a predictor of risk for the de-
velopment of cirrhosis and hepatocellular 
carcinoma, regardless of HBV genotype, 
HBeAg serostatus, and baseline serum 
ALT level.(3,4, 5) 
Licensed oral agents for antiviral therapy 
in patients with chronic hepatitis B virus 
(HBV) infection include lamivudine, ade-
fovir, entecavir, and telbivudine. Emtrici-
tabine, tenofovir, and the combination of 
tenofovir plus emtricitabine in 1 tablet, 
which are licensed for the treatment of 
human immunodeficiency virus infection, 
are additional off-label options for treat-
ing HBV infection. HBV antiviral drug re-
sistance may be best prevented by using 
an agent or combination of agents with a 
high genetic barrier to resistance, and 2 
potent nucleoside and nucleotide drugs 
with different resistance profiles may 
prove to be the optimal first-line treat-
ment for chronic hepatitis B. Frequent 
assessment of quantitative serum HBV 
DNA remains the best approach to early 
detection of resistance, and antiviral 
therapy should be modified as soon as 
resistance is detected.(6)  
Lamivudine is no longer the drug of 
choice because the initial enthusiasm has 
been tempered by the high rate of resis-
tance development. Studies are ongoing 
with the newer generation of antivirals in 
monotherapy or in combination to de-
termine the best strategy for achieving 
rapid and prolonged suppression of viral 
replication. These improved strategies 
should enhance treatment success 
enough to obtain clinical stabilization, to 
delay or prevent the need for transplan-
tation, and to reduce the risk of hepatitis 
B virus recurrence on the graft.(7)  
In this manuscript, the influence of lami-
vudine on CHB treatment, the pattern of 
mutations developed and the associa-
tions of Lamivudine resistance with val-
ues of viral load and alanine aminotrans-
ferase (ALT) were investigated. 
Study design:  
We retrospectively, studied thirty-one 
consecutive chronic hepatitis B patients 
attending to the hepatitis clinic. Patients 
were provided treatment if they had ele-
vated transaminases (i.e. serum ALT, 
AST) levels greater than 1.5 times the 
upper limit of normal for greater than 6 
months and hepatitis B virus (HBV) DNA 
levels of > 105 copies/ml for both hepati-
tis B e antigen (HBeAg) positive and 
negative patients. Patients with decom-
pensated liver disease, defined as clinical 
findings of a variceal hemorrhage, as-
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cites, encephalopathy or portal hyperten-
sion confirmed by ultrasound were ex-
cluded. Also, patients who had received 
previous therapy with either interferon or 
a nucleoside analogue, or with co-
infection with hepatitis C virus, or human 
immunodeficiency virus (HIV), were ex-
cluded. CHB patients (n=31) who had not 
previously received interferon or  nucleo-
side analogue, received lamivudine 100 
mg once daily for a minimum of E12 
months lamivudine (LAM)  therapy and 
followed. The mean time of follow-up of 
patients was 45.5 (21.9) months. They 
visited every 3-month while receiving 
lamivudine. ALT was measured monthly 
and HBVDNA every three months. All pa-
tients were tested for presence of muta-
tion in YMDD motif of viral polymerase 
gene at the end of the first year of 
treatment, and if indicated in rising ala-
nine aminotransferase (ALT) / or 
HBVDNA titer. Peripheral blood samples 
were collected, polymerase chain reac-
tion along with restriction fragment 
length polymorphism (PCR-RFLP) method 
(8) was used to detect mutations in YMDD 
motif. The study performed with agree-
ment of patients for that current treat-
ment and follow-up.  
DNA extraction-HBVDNA was extracted 
from 100 LL of patients' serum samples. 
100 mL of serum sample was diluted in 
150 LL of TES buffer. To this 15 mL of 
10% SDS and 20 LL of proteinase K (20 
mg/ mL) was added and mixture incu-
bated at 60 degree centigrade for one 
hour. After a final extraction with chloro-
form, DNA was precipitated with ethanol 
then dissolved in 50 LL of buffer (10 
mmol Tris-Hcl 1 mmol EDTA PH 8).  Re-
sistance was defined as an increase in 
viral load, with polymerase gene se-
quencing confirming a lamivudine resis-
tance mutation. Viral breakthrough was 
defined as HBV DNA E 5 log10 copies/mL 
on two consecutive visits in patients who, 
on treatment, achieved HBV DNA < 5 
log10 copies/mL. 
Statistical analysis- Data were analyzed 
with SPSS 11.5 software using Student’s 
t test, P2 test and Fisher’s exact test. 
Results: 
Thirty one chronic hepatitis B patients 
were studied. Their mean age was 45.2 
[standard deviation (SD) 13.5] years. 
83.9% of them were male. Baseline HBV 
DNA titer of all patients was high (HBV 
DNA > 5 log10 copies/mL), and in only 4 
patients HBeAg was positive. The mean 
time of follow-up of patients was 45.5 
(SD 21.9) months. Time of mutation 
ranges from 12 to 96 months and its 
mean time was 45.2 (SD 25.3) months. 
Most patients found mutation during time 
period of months 13-24 (29.4%), and 
months 49-72(29.4%). Seventeen pa-
tients (54.8%) had mutations. Distribu-
tion of frequency (%) of CHB subjects 
with mutations after Lamivudine treat-
ment according to time (month), and 
distribution of frequency (%) of muta-
tions after Lamivudine treatment is de-
picted in figure 1, and Figure 2, respec-
tively.  
Mean ALT at time of mutation detection 
was 86.7 (SD 59.3) IU/L, normal range 
(5-35) IU/L.  
45.2% of CHB subjects were sensitive to 
LAM.  There were different viral muta-
tional patterns: 32.3 % YIDD, 3.2% 
YSDD, 12.9% YVDD, and 6.5% mixed-
type YMDD mutants (YVDD, YIDD).  
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Except two patients, all other patients at 
time of detection of YMDD mutation had 
high HBVDNA titer.In five patients with-
out mutation, HBVDNA titer was high. 
The rate of mutation was 11.8, 29.4%, 
17.6%, 29.4%, and 11.8% at < = 12, 
13-24, 25-48, 49-72, and > 72 months, 
respectively. Two patients with mutation 
had undetectable HBVDNA (HBV DNA 
was below the detection threshold < 200 
copies/ml): both patients used immuno-
suppressive drugs and corticosteroids, 
one of them for liver transplantation and 
another for arthritis rheumatoid and 
asthma.  
Because two out of 17 patients at time of 
mutation had undetectable HBVDNA lev-
el, patients who fulfill criteria of Lamivu-
dine resistance ( mutation and high 
HBVDNA titer at time of mutation) were 
15 patients (48%). When resistance was 
defined as an increase in viral load with 
polymerase gene sequencing confirming 
a lamivudine resistance mutation, we had 
15 patients that fulfilled this criteria.  
Of five patients without mutation had 
high HBVDNA titer, three subjects of this 
group had yet indetermined mutation. 
So, the rate of 45.2% sensitive to Lami-
vudine may decrease further by more 
investigating about these five patients. In 
two patients without mutation; last 
HBVDNA titer was not checked.  
The mean age, pretreatment HBeAg ne-
gativity, and high HBVDNA titer at time 
of mutation had significant statistical as-
sociation with occurrence of mutants 
(PV= 0.009, 0.032, 0.049), respectively. 
Sex, baseline and after three months of 
treatment of Lamivudine, AST and ALT 
value, and ALT at time of mutation de-
tection had no significant statistical asso-
ciation with occurrence of mutation. Ta-
ble 1 shows the demographic, biochemi-
cal, and viral load comparison of two 
groups with and without mutation.  
 
Figure 1- Distribution of frequency (%) of CHB subjects with mutations after Lamivudine treatment accord-
ing to time (month)  
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Figure 2 - Distribution of frequencies of mutations after Lamivudine treatment  
Table 1- The demographic, biochemical, and viral load comparison of group with mutation and those without 
mutation after Lamivudine treatment 
 
PV mutation  Variable 
no yes 
0.009 38.5 (12.1) 50.8 (12.3) Mean age (SD) 
1.000 85.7 82.4 Male (%) 
0.652 54.8 (36.1) 60.9 (37.8) Baseline AST 
0.103 55.0 (30.7) 86.5 (68.6) Baseline ALT 
0.032 28.6 0% positive baseline HBeAg 
0.629 60.2 (69.2) 71.2 (49.9) AST after third months of LAM treatment 
0.573 59.6 (53.4) 72.9 (67.1) ALT after third months of LAM treatment 
0.444 62.5 (29.8) 86.7 (59.3) ALT at the time of mutation 
0.049 53.8% 88.2% The last high HBV DNA at the time of mutation 
Discussion: 
The early emergence of lamivudine 
(3TC)-resistant tyrosine-methionine-
aspartate-aspartate (YMDD) mutants has 
been reported during 3TC therapy in pa-
tients with chronic hepatitis B (CHB) in 
hepatitis B virus (HBV)-endemic areas. 
According to a study, YMDD mutation at 
3 months after Lamivudine treatment 
was significantly related to viral break-
through within 24 months.(9) In our 
study, most patients found mutation dur-
ing time period of months 13-24 
(29.4%), and months 49-72(29.4%). 
Detection for HBV mutations at months 
13-24 and 49-72 may be useful to pre-
dict the long-term outcomes of 3TC ther-
apy in CHB patients.  
In a study, of 260 consecutive CHB pa-
tients treated with lamivudine for >12 
months, 231 patients were tested for A 
(1896) variant of HBV using direct se-
quencing. In multivariate analysis, the 
absence of A (1896) variant and high 
serum HBVDNA level were independent 
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factors for viral breakthrough following 
lamivudine therapy. The stop codon mu-
tation at the precore region of HBV in 
addition to low serum HBV-DNA level 
may be associated with low breakthrough 
rate following lamivudine therapy.(10) Dif-
ferent mutational patterns were observed 
in the lamivudine-treated patients with 
and without exacerbation. There was an 
association of the basic core promoter 
and stop codon mutations with lamivu-
dine resistance in patients with disease 
exacerbation.(11)  
Patients who develop YMDD mutant dur-
ing lamivudine therapy for HBV infection 
exhibit various clinical courses. Some 
patients show normal ALT levels, whe-
reas others develop severe hepatitis ex-
acerbations (SHEs) due to YMDD mu-
tants. Negativity for HBeAg at com-
mencement of therapy or before emer-
gence of YMDD mutant was an important 
factor among non-elevated group. Pa-
tients with SHEs had more substitutions 
in the reverse transcriptase (rt) region 
within the polymerase gene at the time 
of exacerbation than those without SHE, 
although no specific substitutions were 
noted. More substitutions in the rt region 
and the other proteins may be related to 
the emergence of severe hepatitis caused 
by lamivudine-resistant virus.(12) In our 
study, ALT level at time of mutation was 
86.7 (SD 59.3) IU/L, and not statistically 
different from those without mutation. 
This finding shows also YMDD mutant is 
accompanied with biochemical relapse 
and breakthrough hepatitis, but it may 
not supposed as sole sign of appearance 
of mutants. Negativity for HBeAg at 
commencement of therapy or before 
emergence of YMDD mutant was an im-
portant factor among our patients. Regu-
lar measurement of HBVDNA titer is 
more important than ALT measurement.  
In a study of 234 chronically HBV-
infected Japanese patients who were 
treated with lamivudine for more than 12 
months, comprised patients with HBV 
genotype A (n = 8), genotype B (n = 
21), genotype C (n = 203) and other 
HBV genotypes (n = 2). Multivariate 
analysis also identified high HBV DNA 
level and HBeAg positivity as factors as-
sociated with emergence of resistance.(13) 
In our study, five patients without YMDD 
mutation had high HBVDNA titer. Hepati-
tis B virus DNA sequences should be ana-
lyzed for pre-S, surface, polymerase, 
core promoter, precore and core regions 
in the undetermined or suspicious sam-
ples.  
In a total of 183 CHB patients, the cumu-
lative rates of viral breakthrough were 
9.6%, 39.0%, 55.8% at 12, 24, and 36 
months, respectively. Serum HBV DNA 
level of 6 months of lamivudine therapy 
and presence of HBeAg were independent 
predictors for viral breakthrough. An al-
ternate therapy should be considered 
when serum viral load is high at 6 
months of lamivudine therapy.(14) Of 79 
patients who had received lamivudine 
therapy for 9-57 months, 34 were 
HBeAg-positive and 45 were HBeAg-
negative; 24 developed virologic break-
through (VBT) and 55 did not. By logistic 
regression, the most important predictor 
of virologic breakthrough was the base-
line HBV DNA (r(2) = 0.12, P < 0.05). 
Lamivudine may remain an effective first 
line therapy for those HBeAg-positive 
patients with a baseline HBV DNA < 6.6 
log (10) copies/mL.(15)  
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In mentioned study, it is not clear why 
used persistent viremia (at 6 months) as 
a criteria for Lamivudine resistance. We 
believe it is better to lower the viral load 
as soon as possible.    
Lamivudine is associated with the risk of 
developing viral mutants and, after ther-
apy discontinuation, to high rate of re-
lapse. In relapsing patients severe acute 
recurrence of hepatitis B may occur. De-
cisions about lamivudine monotherapy 
should take into account the limited long-
term efficacy, effects of relapse, costs 
and predictive factors for response.(16) 
Patients with precore variant hepatitis B 
virus are likely to develop lamivudine 
resistance early and should be consi-
dered for alternate first-line monothera-
py. In the future, combination antiviral 
therapy may limit the development of 
resistance.(17)  
Recent clinical observations reported the 
occurrence of amino acid substitutions at 
position 181 of the HBV polymerase, as-
sociated with a viral breakthrough under 
lamivudine or adefovir therapy. In a 
study, the main variants harboring the 
rtA181T/V mutation isolated from 10 
consecutive patients who developed la-
mivudine and/or adefovir resistance was 
charachterized. The observations suggest 
that a single amino acid change at posi-
tion rt181 may induce cross-resistance to 
lamivudine and adefovir. These data em-
phasize the clinical relevance of genotyp-
ic and phenotypic analysis in the man-
agement of antiviral drug resistance.(18)  
Virologic breakthrough (VBTH) during 
long-term lamivudine therapy is believed 
to be due to the emergence of 
rtYM204I/VDD mutants. Both core pro-
moter and YMDD motif mutation(s) are 
associated with VBTH in patients on long-
term lamivudine therapy. Whether or not 
these promoter mutations in the absence 
of YMDD mutations confer drug resis-
tance needs to be studied in an in vitro 
cell culture system, as they could create 
novel and stronger binding sites for he-
patocyte nuclear factors.(19) 
A study aimed at determining any differ-
ences in the antiviral response and risk of 
YMDD mutations between lamivudine-
treated patients with HBV genotype B 
and genotype C. In conclusion, there was 
no difference in the antiviral response 
and the rate of development of YMDD 
mutations in Chinese patients with geno-
type B and C after 1 year of lamivudine. 
Determination of HBV genotypes before 
lamivudine therapy was probably not an 
important pretreatment investigation to 
predict antiviral responses in Chinese 
patients.(20) In a study, the significance 
of various viral factors and changes of 
viral population with lamivudine treat-
ment was defined. There was no differ-
ence in treatment response between pa-
tients with genotype B and C. Achieving 
HBV DNA levels <1,000 copies/ml at 24 
week is the best target for short- and 
long-term treatment efficacy. Core pro-
moter and precore mutations were asso-
ciated with better treatment outcome, 
and rt256C polymorphism in the polyme-
rase gene with poor response.(21) 
In a study, multivariate analysis showed 
that HBV genotype and pretreatment ALT 
levels was independently associated with 
YMDD mutational patterns. The results 
showed that the YMDD mutational pat-
terns, precore mutation and serum HBV 
DNA levels differ between lamivudine-
resistant HBV genotypes B and C in vivo. 
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It recommended that it is valuable for 
treatment of lamivudine-resistant HBV in 
clinic.(22)  
Pre-therapy viral factors including viral 
load, genotype, precore (PC) stop codon 
status, basal core promoter status and 
pre-S deletion were determined to corre-
late with therapeutic endpoints. For lami-
vudine-treated HBeAg-positive CHB pa-
tients with pre-therapy ALT levels 
>5xULN, the PC stop codon mutation 
could predict a higher HBeAg seroclear-
ance rate at the end of 12-18 months of 
therapy.(23) 
Sequential on-treatment monitoring of 
hepatitis B virus (HBV) DNA levels, 
known as the roadmap concept, might 
predict the efficacy of oral therapy with 
nucleoside/nucleotide analogues among 
patients naive to this treatment.(24) 
Serological markers are key elements in 
diagnosing acute hepatitis B virus (HBV) 
infection and determining its possible 
evolution towards chronicity. Advances in 
the molecular diagnosis of drug resis-
tance using highly sensitive methodolo-
gies such as DNA hybridization assays 
can further pinpoint the type of mutation 
responsible and, more importantly, 
detect upcoming viral resistance at an 
early stage when the variant represents 
only a minor fraction of the total viral 
population.(25)  
HBV shows high rates of turnover in the 
absence of proof-reading ability. As a 
result, large amounts of quasispecies are 
produced naturally or antiviral-
associated. HBV consists of four open 
reading frames, namely preS/S gene, 
precore/core gene, polymerase gene, and 
X gene. Mutations on polymerase genes 
are often induced by antiviral therapy.(26)  
In conclusion, virological and biochemical 
markers (HBeAg, anti-HBe antibodies, 
serum HBVDNA, and serum ALT) are 
used in the diagnosis and monitoring of 
HBV disease. A combined end point of 
biochemical response (ALT normalization) 
and virologic (serum HBV-DNA suppres-
sion) response is used frequently. In this 
study, most of patients were HBeAg neg-
ative CHB on admission. We did not 
study other markers include liver cova-
lently closed circular DNA (cccDNA) and 
quantitative hepatitis B surface antigen 
(HBsAg), HBV genotype, and genotypic 
resistance markers. Also, baseline and 
after mutation detection of necrioinflam-
mation and stage of liver fibrosis was not 
investifgated. Also, lack of define of a 
target serum HBVDNA level, and different 
assays for a patient make the interpreta-
tion difficult. We calculated the amount 
of mutations according to rise of serum 
HBVDNA titer or ALT level and showed it 
in certain divided times. But, in many 
clinical trials resistance is calculated by 
regarding the cumulative probability of 
HBV polymerase mutations. 
In clinical trials, the reporting of resis-
tance has varied tremendously from one 
trial to another. 
The incidence of resistance, which now is 
assessed by sequencing, should be re-
ported as a cumulative probability of oc-
currence. In all clinical trials, the cumula-
tive probability of the onset of (1) resis-
tance, (2) resistance with virologic (HBV 
DNA) breakthrough, and (3) resistance 
with virologic (HBVDNA) and biochemical 
(ALT) breakthroughs, should be reported 
every year according to the duration of 
follow-up evaluation (EB). Calculation 
Archive of SID
www.SID.ir
Shiraz E Medical Journal, Vol. 11, No. 2, April 2010 
 
71 
 
should be made by means of the follow-
ing formula:  
P=1-(1-n1/N1)(1-n2/N2)…(1-nx/Nx) 
where P is the cumulative probability that 
the event will occur, nx is the number of 
cases at 
year x, and Nx is the number of patients 
still followed up at year x.(27,28)  
In present study, most chronic hepatitis 
B patients on Lamivudine treatment de-
veloped mutations in mean 45.2 (SD 
25.3) months. In CHB patients without 
YMDD mutation and high HBVDNA titer, 
analysis for possible new mutants should 
be performed. High HBVDNA titer may be 
supposed as a clue to drug resistant, re-
gardless of ALT level or mutation report.  
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